IMPAKT Breast Cancer Conference Media Alert: Oral presentation abstracts online
The impact of new technologies in the care of patients with breast cancer is at the core of the IMPAKT conference on translational research in breast cancer.
Check oral presentation abstracts (full text) as of Thursday, 8 May 2014 at 10:30 (CEST) http://abstracts.webges.com/impakt2014/myitinerary
Metastatic breast cancer and development of new drugs
While research has made great strides in recent decades to improve and significantly extend the lives of patients with early breast cancer, the needs of patients with advanced or metastatic disease have largely been ignored. In this context the Breast International Group (BIG) has just launched AURORA, which will use molecular screening to improve our understanding of metastatic breast cancer and its response or lack of response to available drug therapies. In total 1,300 women and men from about 60 hospitals in 15 European countries are expected to take part in the programme. Over time, BIG hopes to expand the programme well beyond Europe to involve several thousand more patients.
"It is almost unethical that we continue to treat women with metastatic breast cancer when we have so little knowledge of their disease. We now have powerful technologies for investigating the molecular landscape of tumours, and we have an obligation to women to establish AURORA as a large translational research effort that can hopefully lead to more effective treatments in the future." M. Piccart, Chair of BIG and Director of the Medicine Department of the Institut Jules Bordet, Brussels, Belgium
The AURORA trial will be presented during the session
Saturday, 10 May 2014, 10:45-12:35, Gold Hall
Genomics and the importance of translational research to facilitate the implementation of new discoveries into clinical practice
Patients with estrogen-receptor (ER) positive breast cancer receive hormonal treatments after surgery, but sometimes chemotherapy is also needed. The Multidisciplinary Application of Genomics in Clinical Practice (MAGIC) survey investigated on the criteria used to decide about chemotherapy in this patient population. Results show that criteria vary significantly across Europe.
"Data from the MAGIC survey reveal that 55% of responding physicians have adopted genomic tests in their practice but adoption varies strongly across countries. Of those physicians who have not used them, the vast majority indicate that they would like to use genomic tests in clinical practice but report lack of reimbursement, price and lack of availability as the main barriers to usage, suggesting a substantial need for broader use of genomic tests that provide information beyond traditional measures and can help physicians and patients make more informed treatment decisions." M. Aapro, MAGIC survey Lead Investigator and dean of the Multidisciplinary Oncology Institute, Genolier, Switzerland
The MAGIC survey results will be presented during the
Thursday, 8 May 2014, 17:30-19:00, Gold Foyer
The full conference program is available at http://www.esmo.org/Conferences/IMPAKT-2014-Breast-Cancer/Programme
Around 500 attendees are expected from throughout Europe and the rest of the world.
|Contact: IMPAKT Press Office|
European Society for Medical Oncology